Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K.

J Cyst Fibros. 2019 May 2. pii: S1569-1993(19)30073-6. doi: 10.1016/j.jcf.2019.04.014. [Epub ahead of print]

2.

Less common etiologies of exocrine pancreatic insufficiency.

Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM.

World J Gastroenterol. 2017 Oct 21;23(39):7059-7076. doi: 10.3748/wjg.v23.i39.7059. Review.

3.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

4.

Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.

Ratjen F, Koker P, Geller DE, Langellier-Cocteaux B, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

J Cyst Fibros. 2015 Sep;14(5):608-14. doi: 10.1016/j.jcf.2015.03.004. Epub 2015 Mar 26.

5.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

6.

Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results.

Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS; Tiotropium Cystic Fibrosis Study Group.

PLoS One. 2014 Sep 4;9(9):e106195. doi: 10.1371/journal.pone.0106195. eCollection 2014.

7.

Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis.

Sharma A, Geller DE, Moroni-Zentgraf P, Kattenbeck S, Schmid M, Boland K, Rapp B, Konstan MW, Ratjen F, Elborn JS, Koker P.

Pulm Pharmacol Ther. 2014 Dec;29(2):217-23. doi: 10.1016/j.pupt.2014.08.004. Epub 2014 Aug 24.

PMID:
25161072
8.

Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.

Ting L, Aksenov S, Bhansali SG, Ramakrishna R, Tang P, Geller DE.

CPT Pharmacometrics Syst Pharmacol. 2014 Feb 12;3:e99. doi: 10.1038/psp.2013.76.

9.

The authors reply.

Perry SA, Geller DE, Kesser KC, Selhorst DM, Rendle JK, Hertzog JH.

Pediatr Crit Care Med. 2014 Feb;15(2):186-7. doi: 10.1097/PCC.0000000000000064. No abstract available.

PMID:
24492196
10.

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE; KB001 Study Group.

Pediatr Pulmonol. 2014 Jul;49(7):650-8. doi: 10.1002/ppul.22890. Epub 2013 Sep 9.

11.

Tobramycin inhalation powder in cystic fibrosis patients: response by age group.

Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.

Respir Care. 2014 Mar;59(3):388-98. doi: 10.4187/respcare.02264. Epub 2013 Aug 27.

12.

Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system.

Perry SA, Kesser KC, Geller DE, Selhorst DM, Rendle JK, Hertzog JH.

Pediatr Crit Care Med. 2013 Jun;14(5):e250-6. doi: 10.1097/PCC.0b013e31828a7f79.

PMID:
23628834
13.

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.

Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, Hebestreit HU, Kolbe J, Lapey A, Robinson P, Wu J, Zuckerman JB, Aitken ML; CF301 and CF302 Investigators.

J Cyst Fibros. 2013 Jul;12(4):367-76. doi: 10.1016/j.jcf.2012.11.002. Epub 2012 Dec 9.

14.

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group.

Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672.

15.

The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States.

Colice GL, Ostrom NK, Geller DE, Anolik R, Blaiss M, Marcus P, Schwartz J, Nathan RA.

Ann Allergy Asthma Immunol. 2012 Mar;108(3):157-62. doi: 10.1016/j.anai.2011.12.017. Epub 2012 Jan 31.

PMID:
22374197
16.

Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis.

Geller DE, Madge S.

Respir Med. 2011 Dec;105 Suppl 2:S24-31. doi: 10.1016/S0954-6111(11)70024-5.

17.

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.

Ballmann M, Smyth A, Geller DE.

Respir Med. 2011 Dec;105 Suppl 2:S2-8. doi: 10.1016/S0954-6111(11)70021-X.

18.

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B; CF302 Investigators.

Am J Respir Crit Care Med. 2012 Mar 15;185(6):645-52. doi: 10.1164/rccm.201109-1666OC. Epub 2011 Dec 28.

PMID:
22198974
19.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group.

Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. doi: 10.1164/rccm.201105-0924OC. Epub 2011 Nov 17.

20.

A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.

Stalvey MS, Anbar RD, Konstan MW, Jacobs JR, Bakker B, Lippe B, Geller DE.

Pediatr Pulmonol. 2012 Mar;47(3):252-63. doi: 10.1002/ppul.21546. Epub 2011 Sep 8.

21.

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; Mpex 204 Study Group.

Am J Respir Crit Care Med. 2011 Jun 1;183(11):1510-6. doi: 10.1164/rccm.201008-1293OC. Epub 2011 Feb 25.

PMID:
21471106
22.

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.

Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN.

Antimicrob Agents Chemother. 2011 Jun;55(6):2636-40. doi: 10.1128/AAC.01744-10. Epub 2011 Mar 28.

23.

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.

Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB.

J Cyst Fibros. 2011 Jul;10(4):234-42. doi: 10.1016/j.jcf.2011.02.007. Epub 2011 Mar 26.

24.

Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Geller DE, Weers J, Heuerding S.

J Aerosol Med Pulm Drug Deliv. 2011 Aug;24(4):175-82. doi: 10.1089/jamp.2010.0855. Epub 2011 Mar 11. Review.

25.

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

Vandevanter DR, Geller DE.

Med Devices (Auckl). 2011;4:179-88. doi: 10.2147/MDER.S16360. Epub 2011 Sep 20.

26.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE.

J Cyst Fibros. 2011 Jan;10(1):54-61. doi: 10.1016/j.jcf.2010.10.003. Epub 2010 Nov 12.

27.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.

Pediatr Pulmonol. 2011 Mar;46(3):230-8. doi: 10.1002/ppul.21356. Epub 2010 Oct 20.

28.

A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.

Scherer T, Geller DE, Owyang L, Tservistas M, Keller M, Boden N, Kesser KC, Shire SJ.

J Pharm Sci. 2011 Jan;100(1):98-109. doi: 10.1002/jps.22231. Epub 2010 Jun 8.

PMID:
20533437
29.

The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.

Geller DE, Kesser KC.

J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1:S55-9. doi: 10.1089/jamp.2009.0793.

30.

The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children.

Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, O'Dowd L.

Allergy Asthma Proc. 2010 Jan-Feb;31(1):26-39. doi: 10.2500/aap.2010.31.3301.

PMID:
20167143
31.

Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis.

Driscoll KA, Johnson SB, Barker D, Quittner AL, Deeb LC, Geller DE, Gondor M, Silverstein JH.

J Pediatr Psychol. 2010 Sep;35(8):814-22. doi: 10.1093/jpepsy/jsp138. Epub 2010 Jan 22.

32.

Respiratory care and cystic fibrosis.

Geller DE, Rubin BK.

Respir Care. 2009 Jun;54(6):796-800. Review.

33.

New aerosol delivery devices for cystic fibrosis.

Kesser KC, Geller DE.

Respir Care. 2009 Jun;54(6):754-67; discussion 767-8. Review.

34.

Aerosol antibiotics in cystic fibrosis.

Geller DE.

Respir Care. 2009 May;54(5):658-70. Review.

35.

Respiratory care and cystic fibrosis. Foreward.

Rubin BK, Geller DE.

Respir Care. 2009 May;54(5):586. No abstract available.

36.

Clinical side effects during aerosol therapy: cutaneous and ocular effects.

Geller DE.

J Aerosol Med. 2007;20 Suppl 1:S100-8; discussion S109. Review.

PMID:
17411401
37.

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.

Pediatr Pulmonol. 2007 Apr;42(4):307-13.

PMID:
17352404
38.

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

Tiddens HA, Geller DE, Challoner P, Speirs RJ, Kesser KC, Overbeek SE, Humble D, Shrewsbury SB, Standaert TA.

J Aerosol Med. 2006 Winter;19(4):456-65.

PMID:
17196074
39.

Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis.

Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL.

Respir Care. 2005 Nov;50(11):1438-44.

40.

Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.

Geller DE.

Respir Care. 2005 Oct;50(10):1313-21; discussion 1321-2. Review.

41.

Pulmonary exacerbations in cystic fibrosis.

Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE; Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2004 May;37(5):400-6.

PMID:
15095322
42.

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

Geller DE, Rosenfeld M, Waltz DA, Wilmott RW; AeroDose TOBI Study Group.

Chest. 2003 Jan;123(1):28-36.

PMID:
12527599
43.

New liquid aerosol generation devices: systems that force pressurized liquids through nozzles.

Geller DE.

Respir Care. 2002 Dec;47(12):1392-404; discussion 1404-5.

PMID:
12467498
44.

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW.

Chest. 2002 Jul;122(1):219-26. Review.

PMID:
12114362
45.

Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S.

Pediatr Pulmonol. 1999 Oct;28(4):231-41.

PMID:
10497371
47.

Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.

Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW.

Pediatr Pulmonol. 1998 Feb;25(2):83-7.

PMID:
9516090
48.

Choosing a nebulizer for cystic fibrosis applications.

Geller DE.

Curr Opin Pulm Med. 1997 Nov;3(6):414-9. Review.

PMID:
9391760
49.
50.

Airway responsiveness to cold, dry air in normal infants.

Geller DE, Morgan WJ, Cota KA, Wright AL, Taussig LM.

Pediatr Pulmonol. 1988;4(2):90-7.

PMID:
3380581

Supplemental Content

Loading ...
Support Center